Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul Silva Insider Profile
4 Followers
Paul Silva, SVP & Controller at Vertex Pharmaceuticals, holds 15.10K shares in Vertex Pharmaceuticals (Ticker: VRTX).
Paul Silva Vertex Pharmaceuticals (VRTX)SVP & Controller
Vertex Pharmaceuticals (VRTX)
SVP & Controller
Ranked #54,746 out of 78,624 Corporate Insiders
Profitable Transactions
3 out of 8 Profitable Transactions
Average Return
-8.80%
Average return per transaction
Time Frame
Compare to
Insider Roles
SVP & Controller
Roles that Paul Silva holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Dec 04, 2018 - Dec 04, 2019
Return:+25.80%
The most profitable trade made by Paul Silva
Paul Silva's Trading History
List of latest transactions for each holding click on a transaction to see Paul Silva's performance on stock
You May Also Like
Paul Silva insider profile FAQ
What is the percentage of profitable transactions made by Paul Silva?
The percentage of profitable transactions made by Paul Silva is 38%.
What is the average return per transaction made by Paul Silva?
The average return per transaction made by Paul Silva is -8.80%.
What stocks does Paul Silva hold?
Paul Silva holds: VRTX stocks.
What was Paul Silva’s latest transaction?
Paul Silva latest transaction was an Uninformative Sell of $292.32K.
What was Paul Silva's most profitable transaction?
Paul Silva’s most profitable transaction was an Informative Buy of VRTX stock on December 4, 2018. The return on the trade was 25.80%.
What is Paul Silva's role in Vertex Pharmaceuticals?
Paul Silva's role in Vertex Pharmaceuticals is SVP & Controller.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.